Comparison between Amulet and Watchman left atrial appendage closure devices: A real-world, single center experience.
ACP, Amplatzer Cardiac Plug
AF, Atrial fibrillation
Amulet
Anti-coagulation
Atrial fibrillation
LAA, Left atrial appendage
LAAC, Left atrial appendage closure
Left atrial appendage closure
MACCE, major adverse cardiac and cerebrovascular events
OAC, Oral anticoagulants
TEE, transesophageal echocardiography
Watchman
Journal
International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
03
10
2021
accepted:
13
10
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Data reporting a head-to-head comparison between Amulet and Watchman devices are scarce. The aim of this study was to compare the Watchman™ versus Amulet™ left atrial appendage closure (LAAC) devices in a consecutive, industry-independent registry. Patients who underwent LAAC using Watchman or Amulet devices from January 2014 to December 2019 at the University Heart Center Lübeck, Lübeck, Germany were included in the present analysis. Primary endpoints included periprocedural complications (in-hospital death, pericardial tamponade, device embolization, stroke, major bleeding and vascular access complications), and complications during long-term follow-up (ischemic stroke, hemorrhagic stroke, thromboembolism, device thrombus, bleeding and death). After matching the patients for age (±5 years), gender, CHA2DS2Vasc score (±1) and HASBLED score (±1), each of the Watchman and the Amulet groups included 113 patients. Patients in the Amulet group had significantly more periprocedural complications (2.7% vs 10.6%, p = 0.029; respectively) and more major bleeding complications (0% vs 5.3%, p = 0.029; respectively). During long-term follow-up, the rate of events was comparable between the Watchman and Amulet groups (18.3% versus 20.8%, p = 0.729; respectively). Amulet LAAC device was associated with increased periprocedural complications as compared to Watchman LAAC device. On long-term follow-up, both devices showed comparable efficacy and safety.
Sections du résumé
BACKGROUND
BACKGROUND
Data reporting a head-to-head comparison between Amulet and Watchman devices are scarce. The aim of this study was to compare the Watchman™ versus Amulet™ left atrial appendage closure (LAAC) devices in a consecutive, industry-independent registry.
METHODS
METHODS
Patients who underwent LAAC using Watchman or Amulet devices from January 2014 to December 2019 at the University Heart Center Lübeck, Lübeck, Germany were included in the present analysis. Primary endpoints included periprocedural complications (in-hospital death, pericardial tamponade, device embolization, stroke, major bleeding and vascular access complications), and complications during long-term follow-up (ischemic stroke, hemorrhagic stroke, thromboembolism, device thrombus, bleeding and death).
RESULTS
RESULTS
After matching the patients for age (±5 years), gender, CHA2DS2Vasc score (±1) and HASBLED score (±1), each of the Watchman and the Amulet groups included 113 patients. Patients in the Amulet group had significantly more periprocedural complications (2.7% vs 10.6%, p = 0.029; respectively) and more major bleeding complications (0% vs 5.3%, p = 0.029; respectively). During long-term follow-up, the rate of events was comparable between the Watchman and Amulet groups (18.3% versus 20.8%, p = 0.729; respectively).
CONCLUSION
CONCLUSIONS
Amulet LAAC device was associated with increased periprocedural complications as compared to Watchman LAAC device. On long-term follow-up, both devices showed comparable efficacy and safety.
Identifiants
pubmed: 34712772
doi: 10.1016/j.ijcha.2021.100893
pii: S2352-9067(21)00181-0
pmc: PMC8529070
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100893Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RRT: consultant to Boston Scientific, speaker‘s bureau: Boston Scientific, Abbot Medical. MS: proctor in Boston Scientific for Watchman 2.5 and Watchman FLX. All other authors declare no competing financial and/or non-financial interests in relation to the work described.
Références
BMC Cardiovasc Disord. 2018 Aug 20;18(1):171
pubmed: 30126370
J Am Coll Cardiol. 2013 Jul 9;62(2):96-102
pubmed: 23665098
Cardiol J. 2017;24(2):131-138
pubmed: 28198520
J Am Coll Cardiol. 2017 Dec 19;70(24):2964-2975
pubmed: 29103847
J Cardiol. 2019 Apr;73(4):299-306
pubmed: 30583991
EuroIntervention. 2015 Jan;10(9):1109-25
pubmed: 25169595
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Eur Heart J. 2016 Aug;37(31):2465-74
pubmed: 26822918
J Am Coll Cardiol. 2013 Jun 25;61(25):2551-6
pubmed: 23583249
J Am Coll Cardiol. 2014 Jul 8;64(1):1-12
pubmed: 24998121
Arch Intern Med. 2000 Jan 10;160(1):41-6
pubmed: 10632303
EuroIntervention. 2018 Aug 03;14(5):e590-e597
pubmed: 29806820
J Am Coll Cardiol. 2005 Nov 1;46(9):1729-36
pubmed: 16256877
Heart Rhythm. 2017 Sep;14(9):1302-1308
pubmed: 28577840
Nat Rev Cardiol. 2014 Nov;11(11):639-54
pubmed: 25113750
J Invasive Cardiol. 2012 Nov;24(11):E289-93
pubmed: 23117323
Europace. 2017 Jan;19(1):4-15
pubmed: 27540038
Ann Thorac Surg. 1996 Feb;61(2):755-9
pubmed: 8572814
Lancet. 2009 Aug 15;374(9689):534-42
pubmed: 19683639
J Am Coll Cardiol. 2018 Apr 10;71(14):1528-1536
pubmed: 29622159
Arch Intern Med. 1994 Jul 11;154(13):1449-57
pubmed: 8018000
Circulation. 2021 Aug 30;:
pubmed: 34459659
JAMA. 2001 May 9;285(18):2370-5
pubmed: 11343485
Int J Cardiol. 2017 Dec 1;248:103-107
pubmed: 28797952
EuroIntervention. 2017 Sep 20;13(7):867-876
pubmed: 28649053
EuroIntervention. 2020 Dec 04;16(11):e942-e949
pubmed: 32451320
EuroIntervention. 2016 Apr 20;11(13):1512-21
pubmed: 27107315
Europace. 2014 Mar;16(3):308-19
pubmed: 24351881
Catheter Cardiovasc Interv. 2017 Feb 15;89(3):484-492
pubmed: 27651124
Heart. 2016 Dec 15;102(24):1969-1973
pubmed: 27492943
Ann Intern Med. 1999 Oct 5;131(7):492-501
pubmed: 10507957
Europace. 2020 Jun 1;22(6):916-923
pubmed: 32003774
EuroIntervention. 2017 Apr 20;12(17):2075-2082
pubmed: 27973336
Catheter Cardiovasc Interv. 2017 Mar 1;89(4):763-772
pubmed: 27567013
EuroIntervention. 2016 Feb;11(10):1170-9
pubmed: 25604089
Chest. 2001 Jan;119(1 Suppl):108S-121S
pubmed: 11157645
Europace. 2014 Jan;16(1):6-14
pubmed: 24084680